Patient-oriented Research: Colon CA & Cancer Immunology

以患者为导向的研究：Colon CA

• 批准号: 7097832
• 负责人: RANDALL F HOLCOMBE
• 金额: $ 14.58万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-19 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7097832
• 关键词: cadherins; cancer prevention; colon neoplasms; combination cancer therapy; difluoromethylornithine; flow cytometry; fluorouracil; human subject; human therapy evaluation; in situ hybridization; interleukin 2; leucovorin; levamisole; microarray technology; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence; patient oriented research

DESCRIPTION (provided by applicant): This application is submitted as a competitive renewal of a midcareer investigator award in patient-oriented research (K24CA82450). The PI is Randall F. Holcombe, MD. This application details the experience, qualifications and short- and long-term patient-oriented research plans of Dr. Holcombe, as well as reviews progress during the period of support under the current award. Details about current and planned patient- oriented research is provided. These studies are focused on patient-oriented research in colon cancer and include studies related to the Wnt signaling pathway, elucidation of immunologic events in conjunction with administration of chemotherapy for colon cancer and definition of the mechanisms and potential therapeutic and cancer preventive effects of resveratrol, a naturally occuring compound found in the skin of grapes. Patients with inflammatory bowel disease, having or at high risk for colon cancer, are also studied. An additional clinical trial with laboratory correlative studies, originally designed and written by a mentee hematology-oncology fellow of Dr. Holcombe's involves the treatment of patients with gastric cancer. Mentoring activity over the past 5 years and mentoring plans for the next 5 years are described. The accomplishments of mentees are outlined as are their current activities, especially as related to ongoing participation in patient-oriented research. Ongoing mentoring plans include formal coursework, basic/translational research experiences, instruction in the development and implementation of clinical research trials, and hands-on experiences in clinical research. The original goals and objectives of the current award are reviewed and the extent to which these have been achieved is delineated. Documentation of institutional support and justification of the need for continued support through the K24 mechanism is provided.

描述（由申请人提供）：本申请是作为以患者为导向研究的中级研究员奖（K24CA82450）提交的。 PI是医学博士Randall F. Holcombe。该应用程序详细介绍了Holcombe博士的经验，资格和短期和长期以患者为导向的研究计划，并在当前奖励的支持期间进行了审查。提供了有关当前和计划的以患者为导向的研究的详细信息。这些研究集中在结肠癌的以患者为导向的研究上，包括与Wnt信号通路有关的研究，结合结肠癌的化学疗法的给药以及对机制的定义以及潜在的治疗和癌症预防作用的研究，对白藜芦醇的潜在疗法和癌症预防作用，这是一种自然的葡萄染色性化合物。还研究了患有或高风险结肠癌风险的炎性肠病患者。一项针对实验室相关研究的额外临床试验，最初由霍尔科姆博士的训练者血液肿瘤学研究员设计和撰写，涉及对胃癌患者的治疗。描述了过去5年中的指导活动，并描述了未来5年的指导计划。概述了受训者的成就，以及他们当前的活动，尤其是与持续参与患者研究的研究有关。正在进行的指导计划包括正式课程，基础/翻译研究经验，临床研究试验的开发和实施方面的指导以及临床研究中的动手经验。审查了当前奖励的最初目标和目标，并划定了实现这些奖项的程度。提供了通过K24机制持续支持的机构支持和持续支持的依据。